-
Je něco špatně v tomto záznamu ?
Flavonolignans As a Novel Class of Sodium Pump Inhibitors
M. Kubala, P. Čechová, J. Geletičová, M. Biler, T. Štenclová, P. Trouillas, D. Biedermann,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
Open Access Digital Library
od 2010-01-01
Open Access Digital Library
od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2010
PubMed
27065883
DOI
10.3389/fphys.2016.00115
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
We examined the inhibitory effects of three flavonolignans and their dehydro- derivatives, taxifolin and quercetin on the activity of the Na(+)/K(+)-ATPase (NKA). The flavonolignans silychristin, dehydrosilychristin and dehydrosilydianin inhibited NKA with IC50 of 110 ± 40 μM, 38 ± 8 μM, and 36 ± 14 μM, respectively. Using the methods of molecular modeling, we identified several possible binding sites for these species on NKA and proposed the possible mechanisms of inhibition. The binding to the extracellular- or cytoplasmic C-terminal sites can block the transport of cations through the plasma membrane, while the binding on the interface of cytoplasmic domains can inhibit the enzyme allosterically. Fluorescence spectroscopy experiments confirmed the interaction of these three species with the large cytoplasmic segment connecting transmembrane helices 4 and 5 (C45). The flavonolignans are distinct from the cardiac glycosides that are currently used in NKA treatment. Because their binding sites are different, the mechanism of inhibition is different as well as the range of active concentrations, one can expect that these new NKA inhibitors would exhibit also a different biomedical actions than cardiac glycosides.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16019968
- 003
- CZ-PrNML
- 005
- 20160726103217.0
- 007
- ta
- 008
- 160722s2016 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fphys.2016.00115 $2 doi
- 024 7_
- $a 10.3389/fphys.2016.00115 $2 doi
- 035 __
- $a (PubMed)27065883
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Kubala, Martin $u Department of Biophysics, Faculty of Science, Centre of Region Haná for Biotechnological and Agricultural Research, Palacký University Olomouc, Czech Republic.
- 245 10
- $a Flavonolignans As a Novel Class of Sodium Pump Inhibitors / $c M. Kubala, P. Čechová, J. Geletičová, M. Biler, T. Štenclová, P. Trouillas, D. Biedermann,
- 520 9_
- $a We examined the inhibitory effects of three flavonolignans and their dehydro- derivatives, taxifolin and quercetin on the activity of the Na(+)/K(+)-ATPase (NKA). The flavonolignans silychristin, dehydrosilychristin and dehydrosilydianin inhibited NKA with IC50 of 110 ± 40 μM, 38 ± 8 μM, and 36 ± 14 μM, respectively. Using the methods of molecular modeling, we identified several possible binding sites for these species on NKA and proposed the possible mechanisms of inhibition. The binding to the extracellular- or cytoplasmic C-terminal sites can block the transport of cations through the plasma membrane, while the binding on the interface of cytoplasmic domains can inhibit the enzyme allosterically. Fluorescence spectroscopy experiments confirmed the interaction of these three species with the large cytoplasmic segment connecting transmembrane helices 4 and 5 (C45). The flavonolignans are distinct from the cardiac glycosides that are currently used in NKA treatment. Because their binding sites are different, the mechanism of inhibition is different as well as the range of active concentrations, one can expect that these new NKA inhibitors would exhibit also a different biomedical actions than cardiac glycosides.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Čechová, Petra $u Department of Biophysics, Faculty of Science, Centre of Region Haná for Biotechnological and Agricultural Research, Palacký University Olomouc, Czech Republic.
- 700 1_
- $a Geletičová, Jaroslava $u Department of Biophysics, Faculty of Science, Centre of Region Haná for Biotechnological and Agricultural Research, Palacký University Olomouc, Czech Republic.
- 700 1_
- $a Biler, Michal $u Department of Biophysics, Faculty of Science, Centre of Region Haná for Biotechnological and Agricultural Research, Palacký UniversityOlomouc, Czech Republic; INSERM UMR 850, School of Pharmacy, University LimogesLimoges, France.
- 700 1_
- $a Štenclová, Tereza $u Department of Biophysics, Faculty of Science, Centre of Region Haná for Biotechnological and Agricultural Research, Palacký University Olomouc, Czech Republic.
- 700 1_
- $a Trouillas, Patrick $u INSERM UMR 850, School of Pharmacy, University LimogesLimoges, France; Department of Physical Chemistry, Faculty of Science, Regional Centre of Advanced Technologies and Materials, Palacký UniversityOlomouc, Czech Republic.
- 700 1_
- $a Biedermann, David $u Laboratory of Biotransformation, Institute of Microbiology, Czech Academy of Sciences Prague, Czech Republic.
- 773 0_
- $w MED00174601 $t Frontiers in physiology $x 1664-042X $g Roč. 7, č. - (2016), s. 115
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27065883 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20160726103436 $b ABA008
- 999 __
- $a ind $b bmc $g 1154638 $s 944496
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 7 $c - $d 115 $e 20160330 $i 1664-042X $m Frontiers in physiology $n Front. physiol. $x MED00174601
- LZP __
- $a Pubmed-20160722